Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

Vu H. Duong, Jeffrey E. Lancet, Ezzideen Alrawi, Najla H. Al-Ali, Janelle Perkins, Teresa Field, Pearlie K. Epling-Burnette, Ling Zhang, Alan F. List, Rami S. Komrokji

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P= 0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.

Original languageEnglish (US)
Pages (from-to)510-515
Number of pages6
JournalLeukemia research
Volume37
Issue number5
DOIs
StatePublished - May 2013

Bibliographical note

Funding Information:
RSK was on the Speaker's Bureau and had research funding from Celgene. JEL was a Consultant (Celgene) and received grant funding to institution for efforts from Celgene. AFL was a Consultant and received research funding from Celgene.

Keywords

  • Azacitidine
  • Myelodysplastic syndrome
  • Therapy-related myelodysplastic syndrome
  • Therapy-related myeloid neoplasms

Fingerprint

Dive into the research topics of 'Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models'. Together they form a unique fingerprint.

Cite this